The HER2 protein is overexpressed in 20 to 30% of breast cancers, and recent advances in HER2-directed therapies have revolutionized the treatment of HER2-positive breast cancer in both the early (adjuvant) and advanced (metastatic) settings. However, the HER2 field continues to evolve with the development of various HER2-targeted therapies that will address issues such as treatment resistance, optimal treatment paradigms, and patient quality of life.
Karen A. Gelmon, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Roche
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Roche
Carlos H. Barrios, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche
Served as a speaker or a member of a speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche
Received grants for clinical research from: Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche
Javier Cortés, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Celgene Corporation; Novartis Pharmaceuticals Corporation; Roche
Served as a speaker or a member of a speakers bureau for: Celgene Corporation; Novartis Pharmaceuticals Corporation; Eisai Co., Ltd.; Roche
Paul A. Ellis, MD, FRACP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Novartis; Pfizer Inc.; Roche; Sanofi-Aventis
Served as a speaker or a member of a speakers bureau for: Roche
Nadia Harbeck, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: GlaxoSmithKline; Roche
Served as a speaker or a member of a speakers bureau for: Novartis Pharmaceuticals Corporation; Roche
Joseph Gligorov, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Roche; Eisai Co., Ltd.
Served as a speaker or a member of a speakers bureau for: Novartis Pharmaceuticals Corporation; Roche
Received grants for clinical research from: Novartis Pharmaceuticals Corporation; Roche; Eisai Co., Ltd.